Drugs / OC-L
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02452775 Background | May 2015 → May 2018 | fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma | Abramson Cancer Center at Penn Medicine | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OC-L | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02452775 ↗ |
| Modality | Vaccine | “autologous oxidized tumor cell lysate vaccine (OC-L)” NCT02452775 ↗ |